ArticleNeuroscience letters2015
Yohimbine is a 5-HT1A agonist in rats in doses exceeding 1 mg/kg.
Article in Neuroscience letters, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 33 citations in OpenAlex.
- Antagonism of the antinociceptive effects of fentanyl and the veterinary anesthetic xylazine in mice.The Journal of pharmacology and experimental therapeutics · 2025Article
- The anxiogenic drug yohimbine is a reinforcer in male and female rats.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Article
- Multifaced Nature of Yohimbine-A Promising Therapeutic Potential or a Risk?International journal of molecular sciences · 2024Review
- Exploring the therapeutic effect of core components in Xuanshen Yishen mixture on hypertension through network pharmacology.American journal of translational research · 2024Article
- Blockade of alpha2-adrenergic receptors in the caudal raphe region enhances the renal sympathetic nerve activity response to acute intermittent hypercapnia in rats.Physiological research · 2022Article
- Modulation of Spatial Memory Deficit and Hyperactivity in Dopamine Transporter Knockout RatsFrontiers in psychiatry · 2022Article
- The effects of clonidine and yohimbine in the tail flick and hot plate tests in the naked mole rat (Heterocephalus glaber).BMC research notes · 2021Article
- Investigation of noradrenergic receptor system in anti-nociception using formalin test in the naked mole rat (Heliyon · 2020Article
- Norepinephrine released by intestinal Paneth cells exacerbates ischemic AKI.American journal of physiology. Renal physiology · 2020Article
- Biphasic effects of 5-HTNaunyn-Schmiedeberg's archives of pharmacology · 2019Article
- Impact of obesity on the toxicity of a multi-ingredient dietary supplement, OxyELITE Pro™ (New Formula), using the novel NZO/HILtJ obese mouse model: Physiological and mechanistic assessments.Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association · 2018Article
- Characterization of the locomotor activities of zebrafish larvae under the influence of various neuroactive drugs.Annals of translational medicine · 2018Article
- Faster emergence behavior from ketamine/xylazine anesthesia with atipamezole versus yohimbine.PloS one · 2018Article
- Radioligand binding analysis of αScientific reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Yohimbine is a prototypical alpha2-adrenergic receptor antagonist. Due to its relatively high selectivity, yohimbine is often used in experiments whose purpose is to examine the role of these receptors. For example, yohimbine has been employed at doses of 1-5 mg/kg to reinstate drug-seeking behavior after extinction or to antagonize general anesthesia, an effects presumably being a consequence of blocking alpha2-adrenergic receptors. In this report we characterized dose-dependent autonomic and behavioral effects of yohimbine and its interaction with an antagonist of 5-HT1A receptors, WAY 100,635. In low doses (0.5-2 mg/kg i.p.) yohimbine induced locomotor activation which was accompanied by a tachycardia and mild hypertension. Increasing the dose to 3-4.5 mg/kg reversed the hypertension and locomotor activation and induced profound hypothermia. The hypothermia as well as the suppression of the locomotion and the hypertension could be reversed by the blockade of 5-HT1A receptors with WAY 100635. Our data confirm that yohimbine possesses 5-HT1A properties, and demonstrated that in doses above 1mg/kg significantly activate these receptors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.